HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer?

• Published in: Frontiers in oncology 2020-12, Vol.10, p.572418-572418
• Main Authors: Sun, Yuan-Dong, Zhang, Hao, Chen, Ye-Qiang, Wu, Chun-Xue, Zhang, Jian-Bo, Xu, Hui-Rong, Liu, Jing-Zhou, Han, Jian-Jun
• Format: Article
• Language: English
• Subjects: drug-eluting beads transarterial chemoembolization; high mobility group box 1; HMGB1; liver metastasis of colorectal cancer; Oncology; transarterial chemoembolization
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.572418

HMGB1 is an important mediator of inflammation during ischemia-reperfusion injury on organs. The serum expression of HMGB1 was increased significantly on the 1st day after TACE and decreased significantly which was lower on the 30th day after TACE. Tumor markers of post-DEB-TACE decreased significantly. The correlational analysis showed that patients with low HMGB1 expression had lower risks of fever and liver injury compared those with the higher expression, while the ORR is relatively worse. Patients with lower expression of HMGB1 had longer PFS, better efficacy, and higher quality of life. With the high post-expression, the low expression had lower incidence of fever and liver injury too. There was no statistical difference in the one-year survival among the different groups. The quality of life of all patients was improved significantly. The over-expression of HMGB1 in LMCRC is an adverse prognostic feature and a positive predictor of response to TACE.